Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333 | Sr. VP Chief Financial Officer | November 09, 2020 | November 10, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SUPERNUS PHARMACEUTICALS, INC.
Report date November 09, 2020 · Filed November 10, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,463 |
Ending reported balance
After 2020-11-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-11-09 · Exercise / conversion · Acquired 5,000 · Balance 49,463 F1: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2020. Row 2 · 2020-11-09 · Sale · Disposed 5,000 · Balance 44,463 F1: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2020. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.98 · Expires 2026-03-01 | Direct | 10,000 |
Reported balance
After 2020-11-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-09 · Exercise / conversion · Disposed 5,000 · Balance 10,000 F1: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2020. F2: The option vests in four equal annual installments beginning on March 1, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2020.
F2: The option vests in four equal annual installments beginning on March 1, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 09, 2020 Filed Nov 10, 2020 16:19 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.98 | $0.00 |
DisclosureSEC source: 0001104659-20-123596 · a4.xml · derivative · entry 3 PATRICK GREGORY S · CIK 0001219844 · Sr. VP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2020. F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on March 1, 2017. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 16:19 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 5,000 | $25.00 | $125,000.00 |
DisclosureSEC source: 0001104659-20-123596 · a4.xml · nonDerivative · entry 2 PATRICK GREGORY S · CIK 0001219844 · Sr. VP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,463 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2020. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 16:19 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 5,000 | $12.98 | $64,900.00 |
DisclosureSEC source: 0001104659-20-123596 · a4.xml · nonDerivative · entry 1 PATRICK GREGORY S · CIK 0001219844 · Sr. VP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2020. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 17:43 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.98 | $0.00 |
DisclosureSEC source: 0001104659-20-122611 · a4.xml · derivative · entry 3 PATRICK GREGORY S · CIK 0001219844 · Sr. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 5,000 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2020. F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on March 1, 2017. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 17:43 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 5,000 | $23.00 | $115,000.00 |
DisclosureSEC source: 0001104659-20-122611 · a4.xml · nonDerivative · entry 2 PATRICK GREGORY S · CIK 0001219844 · Sr. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,463 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2020. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 17:43 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 5,000 | $12.98 | $64,900.00 |
DisclosureSEC source: 0001104659-20-122611 · a4.xml · nonDerivative · entry 1 PATRICK GREGORY S · CIK 0001219844 · Sr. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2020. Read SEC document |
| October 15, 2020 Filed Oct 15, 2020 18:04 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $12.98 | $0.00 |
DisclosureSEC source: 0001104659-20-115378 · a4.xml · derivative · entry 3 PATRICK GREGORY S · CIK 0001219844 · Sr. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 15,000 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2020. F3 · derivative.exercise_date: The option vests in four equal annual installments beginning on March 1, 2017. Read SEC document |
| October 15, 2020 Filed Oct 15, 2020 18:04 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 15,000 | $20.03 | $300,507.00 |
DisclosureSEC source: 0001104659-20-115378 · a4.xml · nonDerivative · entry 2 PATRICK GREGORY S · CIK 0001219844 · Sr. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,463 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.0000 to $20.5000, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| October 15, 2020 Filed Oct 15, 2020 18:04 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 15,000 | $12.98 | $194,700.00 |
DisclosureSEC source: 0001104659-20-115378 · a4.xml · nonDerivative · entry 1 PATRICK GREGORY S · CIK 0001219844 · Sr. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2020. Read SEC document |
| August 27, 2020 Filed Aug 28, 2020 16:11 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GiftCommon Stock | 1,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-100179 · a4.xml · nonDerivative · entry 2 PATRICK GREGORY S · CIK 0001219844 · Sr.VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,463 Read SEC document |
| August 25, 2020 Filed Aug 28, 2020 16:11 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-100179 · a4.xml · nonDerivative · entry 1 PATRICK GREGORY S · CIK 0001219844 · Sr.VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,583 F1 · balance_after: Includes an aggregate of 526 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan subsequent to the date of the Reporting Person's most recent filing on Form 4. Read SEC document |
| May 20, 2020 Filed May 20, 2020 18:59 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $12.98 | $0.00 |
DisclosureSEC source: 0001104659-20-064386 · a4.xml · derivative · entry 3 PATRICK GREGORY S · CIK 0001219844 · Sr.VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 15,000 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 26, 2019. F3 · derivative.exercise_date: The option vests in four equal annual installments beginning on March 1, 2017. Read SEC document |
| May 20, 2020 Filed May 20, 2020 18:59 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 15,000 | $25.03 | $375,379.50 |
DisclosureSEC source: 0001104659-20-064386 · a4.xml · nonDerivative · entry 2 PATRICK GREGORY S · CIK 0001219844 · Sr.VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,057 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 26, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.0000 to $25.1700, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| May 20, 2020 Filed May 20, 2020 18:59 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 15,000 | $12.98 | $194,700.00 |
DisclosureSEC source: 0001104659-20-064386 · a4.xml · nonDerivative · entry 1 PATRICK GREGORY S · CIK 0001219844 · Sr.VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 26, 2019. Read SEC document |
| May 08, 2020 Filed May 11, 2020 18:42 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001104659-20-059729 · a4.xml · derivative · entry 3 PATRICK GREGORY S · CIK 0001219844 · Sr VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2025-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 26, 2019. F3 · derivative.exercise_date: The option vests in four equal annual installments beginning on March 3, 2016. Read SEC document |
| May 08, 2020 Filed May 11, 2020 18:42 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 15,000 | $23.14 | $347,034.00 |
DisclosureSEC source: 0001104659-20-059729 · a4.xml · nonDerivative · entry 2 PATRICK GREGORY S · CIK 0001219844 · Sr VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,057 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 26, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.0000 to $23.6700, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| May 08, 2020 Filed May 11, 2020 18:42 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 15,000 | $9.13 | $136,950.00 |
DisclosureSEC source: 0001104659-20-059729 · a4.xml · nonDerivative · entry 1 PATRICK GREGORY S · CIK 0001219844 · Sr VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 26, 2019. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 17:24 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $23.99 | $0.00 |
DisclosureSEC source: 0001104659-20-024847 · a4.xml · derivative · entry 2 PATRICK GREGORY S · CIK 0001219844 · Sr.VP,Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-02-21 F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 21, 2021. Read SEC document |
| July 31, 2019 Filed Aug 1, 2019 17:28 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GiftCommon Stock | 2,590 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-043393 · a4.xml · nonDerivative · entry 1 PATRICK GREGORY S · CIK 0001219844 · Sr. VP,Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,682 F1 · balance_after: Includes an aggregate of 376 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan subsequent to the date of the Reporting Person's most recent filing on Form 4. Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 16:29 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001104659-19-011559 · a4.xml · derivative · entry 3 PATRICK GREGORY S · CIK 0001219844 · Sr VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 20,000 shares Expires 2025-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 28, 2018. F3 · derivative.exercise_date: The option vests in four equal annual installments beginning on March 3, 2016. Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 16:29 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 20,000 | $41.53 | $830,650.00 |
DisclosureSEC source: 0001104659-19-011559 · a4.xml · nonDerivative · entry 2 PATRICK GREGORY S · CIK 0001219844 · Sr VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,896 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 28, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.0000 to $42.1900, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 16:29 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 20,000 | $9.13 | $182,600.00 |
DisclosureSEC source: 0001104659-19-011559 · a4.xml · nonDerivative · entry 1 PATRICK GREGORY S · CIK 0001219844 · Sr VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 28, 2018. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 19:27 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001104659-19-010799 · a4.xml · derivative · entry 2 PATRICK GREGORY S · CIK 0001219844 · Sr.VP,Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-02-22 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 22, 2020. Read SEC document |
| December 03, 2018 Filed Feb 26, 2019 18:59 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GiftCommon Stock | 8,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-010791 · a5.xml · nonDerivative · entry 1 PATRICK GREGORY S · CIK 0001219844 · Sr.VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,896 F1 · balance_after: Includes an aggregate of 521 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan subsequent to the date of the Reporting Person's most recent filing on Form 4. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 15:27 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001104659-18-043825 · a4.xml · derivative · entry 5 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 15,000 shares Expires 2025-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 1, 2018. F4 · derivative.exercise_date: The option vests in four equal annual installments beginning on March 3, 2016. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 15:27 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001104659-18-043825 · a4.xml · derivative · entry 4 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2024-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 1, 2018. F3 · derivative.exercise_date: The option vests in four equal annual installments beginning on January 21, 2015. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 15:27 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 35,000 | $56.63 | $1,981,913.50 |
DisclosureSEC source: 0001104659-18-043825 · a4.xml · nonDerivative · entry 3 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,975 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 1, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.0000 to $58.5500, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 15:27 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 15,000 | $9.13 | $136,950.00 |
DisclosureSEC source: 0001104659-18-043825 · a4.xml · nonDerivative · entry 2 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 1, 2018. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 15:27 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 20,000 | $9.24 | $184,800.00 |
DisclosureSEC source: 0001104659-18-043825 · a4.xml · nonDerivative · entry 1 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 1, 2018. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 16:58 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $39.40 | $0.00 |
DisclosureSEC source: 0001104659-18-010414 · a4.xml · derivative · entry 2 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-02-14 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 14, 2019. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 16:32 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001104659-18-002075 · a4.xml · derivative · entry 7 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 30,000 shares Expires 2024-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 12, 2017. F6 · derivative.exercise_date: The option became exercisable in four equal installments beginning on January 21, 2015, which was the first anniversary of the date on which the option was granted. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 16:32 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-18-002075 · a4.xml · derivative · entry 6 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 12, 2017. F5 · derivative.exercise_date: The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 16:32 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.88 | $0.00 |
DisclosureSEC source: 0001104659-18-002075 · a4.xml · derivative · entry 5 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2021-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 12, 2017. F4 · derivative.exercise_date: The option became exercisable in four equal installments beginning on December 30, 2012, which was the first anniversary of the date on which the option was granted. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 16:32 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 50,000 | $43.56 | $2,178,145.00 |
DisclosureSEC source: 0001104659-18-002075 · a4.xml · nonDerivative · entry 4 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,975 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 12, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.2500 to $43.8500, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 16:32 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 30,000 | $9.24 | $277,200.00 |
DisclosureSEC source: 0001104659-18-002075 · a4.xml · nonDerivative · entry 3 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 12, 2017. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 16:32 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 20,000 | $7.90 | $158,000.00 |
DisclosureSEC source: 0001104659-18-002075 · a4.xml · nonDerivative · entry 2 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 12, 2017. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 16:32 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 25,000 | $5.88 | $147,000.00 |
DisclosureSEC source: 0001104659-18-002075 · a4.xml · nonDerivative · entry 1 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 12, 2017. F2 · balance_after: Includes an aggregate of 259 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan subsequent to the date of the Reporting Person's most recent filing on Form 4. Read SEC document |
| September 08, 2017 Filed Sep 11, 2017 19:23 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $5.88 | $0.00 |
DisclosureSEC source: 0001104659-17-056611 · a4.xml · derivative · entry 11 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 15,000 shares Expires 2021-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017. F6 · derivative.exercise_date: The option became exercisable in four equal installments beginning on December 30, 2012, which was the first anniversary of the date on which the option was granted. Read SEC document |
| September 08, 2017 Filed Sep 11, 2017 19:23 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 23,481 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-17-056611 · a4.xml · derivative · entry 10 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 23,481 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017. F5 · derivative.exercise_date: The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted. Read SEC document |
| September 08, 2017 Filed Sep 11, 2017 19:23 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 15,000 | $5.88 | $88,200.00 |
DisclosureSEC source: 0001104659-17-056611 · a4.xml · nonDerivative · entry 7 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017. Read SEC document |
| September 08, 2017 Filed Sep 11, 2017 19:23 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 23,481 | $48.89 | $1,147,964.96 |
DisclosureSEC source: 0001104659-17-056611 · a4.xml · nonDerivative · entry 6 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,716 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.6000 to $49.3500, inclusive. The reporting person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document |
| September 08, 2017 Filed Sep 11, 2017 19:23 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 23,481 | $7.90 | $185,499.90 |
DisclosureSEC source: 0001104659-17-056611 · a4.xml · nonDerivative · entry 5 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 19:23 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $5.88 | $0.00 |
DisclosureSEC source: 0001104659-17-056611 · a4.xml · derivative · entry 9 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 15,000 shares Expires 2021-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017. F6 · derivative.exercise_date: The option became exercisable in four equal installments beginning on December 30, 2012, which was the first anniversary of the date on which the option was granted. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 19:23 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 26,519 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-17-056611 · a4.xml · derivative · entry 8 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,481 Underlying: Common Stock · 26,519 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017. F5 · derivative.exercise_date: The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 19:23 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 15,000 | $5.88 | $88,200.00 |
DisclosureSEC source: 0001104659-17-056611 · a4.xml · nonDerivative · entry 4 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 19:23 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 1,519 | $48.00 | $72,912.00 |
DisclosureSEC source: 0001104659-17-056611 · a4.xml · nonDerivative · entry 3 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 716 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 19:23 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 25,000 | $46.36 | $1,158,902.50 |
DisclosureSEC source: 0001104659-17-056611 · a4.xml · nonDerivative · entry 2 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,235 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.0000 to $47.3500, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 19:23 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 26,519 | $7.90 | $209,500.10 |
DisclosureSEC source: 0001104659-17-056611 · a4.xml · nonDerivative · entry 1 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017. F2 · balance_after: Includes an aggregate of 495 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan subsequent to the date of the Reporting Person's most recent filing on Form 4. Read SEC document |
| April 24, 2017 Filed Apr 26, 2017 16:17 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $5.88 | $0.00 |
DisclosureSEC source: 0001104659-17-026371 · a4.xml · derivative · entry 3 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 50,000 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 22, 2017. F3 · derivative.exercise_date: The option became exercisable in four equal installments beginning on December 30, 2012, which was the first anniversary of the date on which the option was granted. Read SEC document |
| April 24, 2017 Filed Apr 26, 2017 16:17 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 54,000 | $32.37 | $1,747,872.00 |
DisclosureSEC source: 0001104659-17-026371 · a4.xml · nonDerivative · entry 2 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 22, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.2500 to $32.7500, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.